Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 14/20 | 1.00 |
| ▸ | MAOA | P21397 | 4/20 | 0.71 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.69 |
| ▸ | NPC1 | O15118 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.60 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.60 |
| ▸ | IDO1 | P14902 | 1/20 | 0.60 |
| ▸ | AGXT | P21549 | 1/20 | 0.60 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29666660 | 0.90 | MAOB (1.00) | MAOBMAOAMRGPRX4NPC1ALDH1A1 | |
| SCHEMBL13469158 | 0.90 | MAOB (0.82) | MAOBMAOAMRGPRX4PARP15PARP10 | |
| SCHEMBL73864 | 0.90 | MAOB (1.00) | MAOBMAOAMRGPRX4NPC1ALDH1A1 | |
| SCHEMBL17978716 | 0.89 | MAOB (0.96) | MAOBMAOAMRGPRX4NPC1ALDH1A1 | |
| SCHEMBL810741 | 0.88 | MAOB (0.77) | MAOBMAOAMRGPRX4NPC1ALDH1A1 | |
| SCHEMBL16795550 | 0.88 | MAOB (1.00) | MAOBMAOAMRGPRX4PARP15 | |
| SCHEMBL810530 | 0.88 | MAOB (0.77) | MAOBMAOAMRGPRX4NPC1ALDH1A1 | |
| SCHEMBL16795515 | 0.88 | MAOB (1.00) | MAOBMAOAMRGPRX4NPC1ALDH1A1 | |
| SCHEMBL16795545 | 0.88 | MAOB (0.88) | MAOBMAOAMRGPRX4PARP15PARP10 | |
| SCHEMBL16795652 | 0.88 | MAOB (0.88) | MAOBMAOAMRGPRX4IDO1AGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7553809-B2 | Fc receptor modulators and uses thereof | ILEXUS PTY LIMITED (AU) | 2009-06-30 | — | — | US | disclosed |
| US-20060057144-A1 | Fc receptor modulators and uses thereof | ILEXUS PTY LIMITED (AU) | 2006-03-16 | — | — | US | disclosed |
| US-6835753-B2 | Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt | ILEXUS PTY LIMITED (AU) | 2004-12-28 | — | — | US | disclosed |
| EP-1109545-A4 | Fc RECEPTOR MODULATORS AND USES THEREOF | ILEXUS PTY LTD (AU) | 2004-11-10 | — | — | EP | disclosed |
| US-20020061844-A1 | Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt | ILEXUS PTY LIMITED | 2002-05-23 | — | — | US | disclosed |
| US-6355683-B1 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE | ILEXUS PTY LIMITED (AU) | 2002-03-12 | — | — | US | disclosed |
| EP-1109545-A1 | Fc RECEPTOR MODULATORS AND USES THEREOF | ILEXUS PTY LTD (AU) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000015214-A1 | Fc RECEPTOR MODULATORS AND USES THEREOF | ILEXUS PTY LIMITED (US) | 2000-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061844-A1 | Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt | FCGR2A, FCGR1A, FCER2 | MAOB 1355/4885MAOA 748/4885MRGPRX4 98/4885 |
| US-20060057144-A1 | Fc receptor modulators and uses thereof | FCGR1A, FCER2, FCGR2A | MAOB 1334/4885MAOA 1307/4885MRGPRX4 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.